Drugs in MeSH Category Estrogen Antagonists

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Granata Bio Corp	MILOPHENE	clomiphene citrate	TABLET;ORAL	072196-001	Dec 20, 1988	AB	RX	No	No
Barr	DANAZOL	danazol	CAPSULE;ORAL	074582-002	May 29, 1998	AB	RX	No	No
Apotex	TAMOXIFEN CITRATE	tamoxifen citrate	TABLET;ORAL	090878-001	Sep 23, 2011		DISCN	No	No
Mayne Pharma Commrcl	SOLTAMOX	tamoxifen citrate	SOLUTION;ORAL	021807-001	Oct 29, 2005		RX	Yes	Yes
Sanofi Aventis Us	DANOCRINE	danazol	CAPSULE;ORAL	017557-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Lannett Co Inc	DANAZOL	danazol	CAPSULE;ORAL	077246-002	Apr 19, 2007	AB	RX	No	No
Actavis Labs Fl Inc	TAMOXIFEN CITRATE	tamoxifen citrate	TABLET;ORAL	070929-001	Feb 20, 2003	AB	RX	No	No

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Estrogen Antagonists

Last updated: April 25, 2026

What is the NLM MeSH “Estrogen Antagonists” drug universe?

NLM MeSH “Estrogen Antagonists” maps to anti-estrogen pharmacology, dominated by steroidal estrogen receptor (ER) antagonists (notably selective ER degraders are typically classified elsewhere) and ER antagonists used across oncology, infertility, and off-label hormone suppression.

Common active ingredients inside the practical market scope (oncology and endocrine):

• Fulvestrant (ER antagonist/degrader; marketed as steroidal ER antagonist)
• Tamoxifen (ER modulator, antagonist in breast tissue)
• Toremifene (ER modulator)
• Clomifene (anti-estrogen effect in hypothalamus, used for ovulation induction)
• Raloxifene (ER modulator; reduces ER-positive breast cancer risk)
• Bazedoxifene (ER modulator; osteoporosis with breast cancer risk modulation)
• Other ER antagonists/withdrawn agents may exist, but the investable, spend-relevant set is led by fulvestrant and SERMs (tamoxifen/toremifene/raloxifene, plus clomifene for fertility).

How does the market move: demand drivers, pricing pressure, and competitive structure?

Demand drivers

Oncology remains the volume anchor for estrogen-antagonist spend:

• ER-positive breast cancer is the largest use case for ER antagonists and SERMs.
• Fulvestrant captures a growing share in metastatic disease lines where switching after endocrine therapy resistance is relevant.

Non-oncology use is steady but smaller:

• Fertility treatment uses clomifene.
• Osteoporosis and breast cancer risk reduction uses raloxifene and bazedoxifene.

Pricing pressure

• Old generics dominate price levels for tamoxifen and many SERM formats, creating a floor and compressing revenue pools around the drug rather than the indication.
• Fulvestrant pricing holds better because of its formulation and route (injectable) complexity and fewer direct interchangeables.

Competitive structure

• High fragmentation on SERMs (multiple generics, fixed-dose tablets) vs.
• More concentrated competition for fulvestrant due to formulation incumbency and payers’ preference for established administration regimens.

Where growth is most investable

Growth tends to shift from legacy SERM markets toward:

• Line extensions (earlier-stage adoption or broader metastatic settings where clinical utility is established).
• Substitution-proof delivery platforms (lower injection burden, improved pharmacokinetics, or enhanced tolerability).

What is the patent landscape shape: what is protected and for how long?

The patent landscape for estrogen antagonists is typically a stack:

1. Active pharmaceutical ingredient (API) composition-of-matter (often expired for tamoxifen-class generics; varies for fulvestrant depending on filing series).
2. Formulation and process patents (device-like protection for injectables, sustained-release, concentration, and manufacturing).
3. Method-of-use (new indications, dosing schedules, combinations, and sequencing).
4. Regulatory exclusivities (jurisdiction-specific: data exclusivity and pediatric extensions depending on filing years and pathways).

Primary patents you track in this space

For business decisions, the most actionable patent families are:

• Fulvestrant formulation families (pre-filled syringes, injection composition, and controlled release or stability improvements).
• Fulvestrant dosing regimen families (including dose reduction, loading schemes, and schedule adjustments).
• Method-of-use families for ER-positive disease (adjuvant/metastatic settings, combination with CDK4/6 inhibitors, PI3K pathway agents, or targeted therapies).

For SERMs:

• Tamoxifen and toremifene are generally mature, with fewer remaining API levers.
• Clomifene and raloxifene similarly skew toward generic freedom-to-operate rather than heavy new IP—unless a company builds on new salt forms, crystalline forms, or novel dosing.

Where do patent expirations concentrate, and what does that mean for entry timing?

In this class, the practical entry timing hinges on not just API expiration, but:

• Formulation and device/regimen patents (especially for injectables).
• Indication exclusivity (if a new use is still under statutory/regulatory protection).
• Patent thickets around combination regimens and sequencing.

Business interpretation:

• Generic SERMs face low remaining barriers.
• Fulvestrant follow-on development has a more complex freedom-to-operate environment, where “generic” depends on proving bioequivalence and navigating formulation and method-of-use claims.

How do generics and biosimilars interact with ER-antagonist patents?

• SERMs are small molecules and compete through ANDA-style pathways where patent life is mostly method-of-use and formulation.
• Fulvestrant is injectable and competes as a generic if patents permit and regulatory pathways align. Even when the API is mature, patents on presentation and dosing schedule can create delay.

What does the clinical and regulatory pipeline imply for future patents?

ER antagonists still attract pipeline IP because:

• Mechanism-driven combinations keep creating new “method-of-use” opportunities (switching strategies, sequencing after progression, and combination with targeted oncology agents).
• Patient subgrouping (based on biomarkers and prior endocrine exposure) supports new claims and can extend market exclusivity.

Which companies and product archetypes define the competitive set?

Fulvestrant incumbency

• Incumbent commercial products set the benchmark dosing schedule and formulation standard.
• Follow-on entrants typically target:
  • lower injection volume
  • prefilled device formats
  • simplified dosing schedules
  • improved tolerability (less injection-site pain through excipient tweaks)

SERM ecosystem

• Generic manufacturers dominate.
• New patents typically come from:
  • new salt/crystal forms
  • new fixed-dose combinations
  • new dosing intervals
  • new indication support (risk-reduction or specific endocrine indications)

Patent landscape: what categories most likely remain active?

1) Composition and formulation (API-specific and delivery-specific)

• For fulvestrant-like injectables, the strongest post-API protection usually sits in:
  • composition stability
  • particle size control (if applicable)
  • emulsions and excipient system refinements
  • prefilled device and container closure systems (where claimed)

2) Method-of-use

• Most active in oncology where:
  • new indication expansions occur
  • combinations are validated
  • patient selection criteria tighten

3) Dosing and administration regimen

• Dosing schedules can carry their own claims, especially if they show non-inferiority, improved tolerability, or operational benefit.

Key market/patent link: what moves the value of a new entrant?

A new entrant’s value is driven by:

• Freedom-to-operate strength (especially for fulvestrant formulations and regimen claims)
• payer uptake (availability of an equivalent regimen matters)
• execution risk (manufacturing of injectable emulsions is a bottleneck)

What are the primary strategic moves implied by the landscape?

For originator companies

• Protect new uses and combinations rather than relying solely on API.
• Use formulation stewardship to sustain competitive position as generics reach market.

For generic and follow-on developers

• Map claims in three dimensions:
  1. API composition
  2. formulation and device/presentation
  3. dosing and method-of-use
• Focus on route and presentation equivalence plus claim clearance.

For investors

• The investable opportunity is less about “ER antagonists in general” and more about:
  • injectable fulvestrant follow-ons
  • new combination regimens that create method-of-use patent headroom
  • incremental improvements that keep physicians within the incumbent prescribing framework

Market snapshots by utilization segment (directional, decision-relevant)

Oncology

• Highest revenue concentration
• Patent battles most visible in fulvestrant-like injectable ecosystems
• Growth depends on line-of-therapy positioning and biomarker-defined populations

Fertility

• Clomifene remains a core inexpensive therapy
• Patent leverage is limited; competition is generic-driven

Bone health and breast cancer risk

• SERMs like raloxifene and bazedoxifene drive stable demand
• Patent leverage is mostly incremental; market is payer and guideline sensitive

Key Takeaways

• The MeSH class “Estrogen Antagonists” is economically dominated by ER-directed endocrine oncology, with fulvestrant setting the highest patent and formulation complexity.
• SERMs (tamoxifen, toremifene, clomifene, raloxifene, bazedoxifene) are mature and typically generic-price dominated, with remaining IP often centered on formulation or method-of-use, not API.
• For fulvestrant, patent value sits in formulation, device/presentation, dosing regimen, and method-of-use claims, shaping entry timing and payer adoption.
• Competitive strategy and investment focus should prioritize freedom-to-operate across formulation and dosing, not only API expiration.

FAQs

1) Which ER antagonist product most concentrates patent risk in this MeSH class?

Fulvestrant concentrates the most patent and formulation/regimen complexity in practical market access because its injectable presentation creates a denser protection stack.

2) Why do generic SERMs typically face less patent friction than fulvestrant follow-ons?

Tamoxifen and related SERMs are small-molecule generics with widely matured API protection; remaining IP is usually limited to incremental formulation or method-of-use claims.

3) What patent category most often delays follow-on injectable entry for fulvestrant?

Formulation and presentation claims, followed by dosing regimen and method-of-use claims, are the most operationally relevant.

4) Does market growth come from new molecules or from expanded indications?

For estrogen antagonists, growth usually comes more from indication and regimen expansion and from combination positioning than from entirely new molecular classes.

5) What diligence steps matter most for an entrant targeting this class?

Claim mapping must cover API, formulation/presentation, dosing regimen, and method-of-use, then align those findings with regulatory bioequivalence and payer regimen preferences.

---

References

[1] U.S. National Library of Medicine. MeSH Browser. “Estrogen Antagonists.” https://meshb.nlm.nih.gov/
[2] FDA. Drug Approval Packages and related labeling for estrogen antagonists (tamoxifen, toremifene, clomifene, raloxifene, bazedoxifene, fulvestrant). https://www.accessdata.fda.gov/scripts/cder/daf/
[3] U.S. FDA. Orange Book: Approved Drug Products With Therapeutic Equivalence Evaluations (search by active ingredient and exclusivity). https://www.accessdata.fda.gov/scripts/cder/ob/